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A third of the world’s population is exposed to Mycobacterium tuberculosis in their lifetime. Over eight million
people develop a tuberculosis (TB) illness and 1.3 million people die from the disease every year. Acquired
immunity (cytotoxic CD8+ T cells (CBT), Th1 CD4+ helper T cells) macrophages, and dendritic cells all play
important roles in TB infection. Recently, it is well established that innate immunity as well plays a definitive role in
the development of TB immunity under the effects of several cytokines, microbicidal proteins and Toll-like receptors.
Meanwhile, the introduction and widespread use of biological disease-modifying anti-rheumatic reagents over the
last 15 years worldwide has dramatically advanced and improved the standard care and prognosis of patients with
rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
However, as clinical experience with these drugs has grown, the risk of granulomatous infections, especially
disseminated TB and fungal infections, has become apparent, especially because having RA or JIA may innately
increase the risk of infection (bacterial, viral and fungal). The knowledge of basic immunology has also advanced
over the past 10 years and adult and pediatric rheumatologists should increase their understanding of this dynamic
between arthritis diseases, anti-TNF- α medications, and TB. This review will provide an up-to-date discussion of
both the immunology of the TB organism in the human host and the pathophysiologic mechanisms of the TNF-α
blockers in the development of secondary (disseminated) tuberculosis.
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Biological reagents (so-called “biologics”) target cytokines
and cell surface proteins. The use of these biological re-
agents has brought impressive and revolutionary improve-
ments in clinical outcomes in the medical care of many
rheumatic diseases, especially rheumatoid arthritis (RA)
and juvenile idiopathic arthritis (JIA) as well as inflamma-
tory bowel disease. Last year (2013) marks the tenth anni-
versary of the approval of the first tumor necrosis factor
(TNF)-α antagonist for the treatment of RA in Japan.
Clinical side effects have been tracked in Japan and other
countries since the biologics were authorized and mar-
keted as anti-rheumatic and/or immune-modulatory
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unless otherwise stated.The remarkably high incidence of tuberculosis (TB) in
patients treated with TNF-α antagonists raises the intri-
guing question of the physiological role of TNF-α in the
immune response [1-6]. There are several cytokines
involved in the pathogenesis of RA including TNF-α. As
the pathological role of TNF-α has become better under-
stood, the physiological role of TNF-α in maintaining
the latency of TB in granulomas in infected people has
also been better clarified [4-6].
In the present manuscript, the articles about immunity
against TB infections are reviewed and the information
that should be kept in mind to ensure the suitable and
safe use of biologics is described.Review
Tuberculosis
A third of the world’s population is exposed to Mycobac-
terium tuberculosis. A clinical TB illness developed in 8.6
million people in 2012 and according to the statistics ofis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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from the disease every year worldwide [7]. Secondary TB,
which follows primary TB, develops after the incubation
period (latent infection). Re-activated TB disease often
leads to secondary dissemination. Primary TB with the
Ghon’s complex as well as hilar and cervical lymph node
TB and pleurisy develops in approximately 0.5-1.0% of
infected people, and the remaining are in a state of latent
infection (latency) (Figure 1) [4,8]. People infected with TB
bacilli are usually asymptomatic during latent infection,
and secondary TB develops in 10% of those by endo-
genous reactivation. Each granuloma contains viable TB
bacilli; most likely, throughout the lifetime of the host, the
maintenance of the granuloma is a prerequisite to allowing
continued protection from the bacilli [2,4,8]. Factors
disrupting the fine-tuned balance between mycobacteria
and the maintenance of the granuloma will inevitably raise
the risk of reactivation of the disease.
Most cases of adult disseminated TB are secondary
tuberculosis induced by endogenous reactivation. Failure of
the host immune mechanism (due to HIV infection, dosage
of immunosuppressant medication, malnutrition, aging,
and perhaps other unknown factors) could bring the onset
of secondary TB. Certainly, the use of anti-TNF-α antibody
drugs specifically may be a trigger (Figure 2).Immune response to tb and the mechanism of sterization
of the tb bacilli
The understanding of the immune responses to TB bacilli
has advanced during the past several years. Our present
understanding is as follows:Figure 1 Progression of M. tuberculosis infection. The relationship betw
possibility of the onset of disease. Reactivation is triggered by AIDS, DM, stAlveolar macrophages and epithelium cells
The bacilli are often ingested by alveolar macrophages
after invading the lung tissue. The TB bacilli may also
invade human alveolar epithelium cells through the action
of mammalian cell entry protein on the cell surface [9,10].
Induction of reactive nitrogen intermediates
In mice, the combination of the T-cell derived cytokine
interferon-γ (IFN-γ) and TNF-α first induces antimicro-
bial activity in macrophages via the induction of reactive
nitrogen intermediates (peroxynitrite) and killing peptides
(defensin, cathelicidin) [11-13]. Superoxide anion produc-
tion in phagocytes can sterilize the bacteria; however, these
anions are not strong enough to kill tuberculosis bacilli
because of the strong catalase activity and superoxide
dismutase (SOD) action of the bacilli, through which the
bacilli directly scavenge oxygen radicals [14,15].
TNF-α activity
IFN-γ and TNF-α are mainly produced from dendritic cells
(DCs) and the activated macrophages [16,17]. One of the
major functions of TNF-α is the recruitment of monocytes
and circulating antigen-specific T lymphocytes to the site of
TB infection. TNF-α directs leukocyte movement, includ-
ing its action on the vascular endothelium (intracellular
adhesion molecule) and on the establishment of chemokine
gradients [16-18]. TNF-α additionally activates CD8+ cyto-
toxic T cells (CTLs) that may be important because these
cells release granulysin and directly kill intracellular bacteria
[19]. TNF-α also promotes the maturation of monocytes to
dendritic cells (DCs) and/or macrophages, inducing the
antigen presentation of intracellular mycobacteria. TNF-αeen primary tuberculosis, latency, and reactivated tuberculosis and the
eroids, anti-TNF blockers, aging, and possibly other unknown factors.
Figure 2 Invasion of mycobacterium bacilli and the process of the onset of disease. The relationship between cytokines and
immunoregulatory cells. Abbreviations: TB, tuberculosis; IFN, interferon; TNF, tumor necrosis factor; CTL, cytotoxic T lymphocytes.
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natural killer (NK) cells and γδ T cells gather at the infec-
tion site and bring their activation. The activated CTL cells
have the ability to produce perforin protein and TNF-α by
itself, which guide TB-infected monocytes to apoptosis,
which involves intracellular living TB bacilli, and to induce
the autophagy of infected cells via activated macrophages
[20] (Figure 3).Figure 3 Innate immunity and adaptive immunity in tuberculosis. Abb
factor; CTL, cytotoxic T lymphocytes; IL, interleukin; Th, T helper.The role of dendritic cells
DCs are present in the epithelial layers, including the
alveolar spaces in the lung, where they create a tight
surveillance network [21,22]. DCs have a special role in
initiating T cell responses in TB infection. Local alveolar
macrophages are poor antigen-presenting cells prior to
their differentiation into DCs [23,24]. This localization
suggests that DCs present a first line of defense againstreviations: MΦ, macrophage; IFN, interferon; TNF, tumor necrosis
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process of antigen presentation [18].
Granuloma formation
Granuloma formation can prevent infectious expansion
(dissemination). Langhans giant cells, lymphocytes, fibro-
blast cells surround the ingested TB bacteria [3,18,25] and
in the presence of TNF-α, a granuloma is then effectively
formed (Figures 4 and 5). The TB bacillus is captured in a
granuloma but can survive inside [26]. The space is re-
placed by the caseation organization, and in most cases,
the TB bacillus remains in a dormant state (latent infec-
tion). Caseation organization is exaggerated in the pres-
ence of TNF-α.
Risk of biologics and tuberculosis
Rheumatic disease itself is associated with an increased
risk for TB without the use of anti-TNF-α medications
(approximately 2–4 times [27]). Seong and others have
reported that the TB onset risk ratio in a population
with rheumatic disease treated with infliximab in South
Korea rose from 8.9 fold (95% CI, 4.6-17.2) to 30.1 fold
[28]. Keane and colleagues published results based on
the FDA Adverse Event Reporting System. They found
70 cases of TB in 147,000 patients who had received the
treatment with infliximab, a TNF-α neutralizer [1]. The
estimated rate of TB among patients with rheumatoid
arthritis in United States is 24.4 cases per 100,000.
The infliximab-associated cases had unusual characteris-
tics that may have caused the TB infection to be especially
severe; 40 out of 70 cases presented extrapulmonary dis-
ease (17 of which were disseminated). The median interval
between starting infliximab and the development of infec-
tion was only 12 weeks; this finding supports the conten-
tion that the use of this TNF inhibitor is strongly
associated with the reactivation of latent tuberculosis into
secondary tuberculosis. The tuberculosis risk ratio for ada-
limumab, which is a humanized antibody against TNF-α,Figure 4 The experimental cell cultures with several cytokines. The ch
GM-CSF (20 ng/mL) and IL-4 (20 ng/mL) in the presence or absence of TNF
May-Grünwald-Giemsa-stained monocyte-derived cells (10x) are shown and
granulocyte/macrophage colony-stimulating factor. Abbreviations: IL-4, intewas reported to be even higher at 19.9 (95% CI, 16.2-24.8)
fold according to the data for a Spanish population [6,29].
A similar number of people have been exposed to eta-
nercept, and only nine cases of tuberculosis were reported
at that time (p < 0.05). Using data collected from the ad-
verse event reporting system of the FDA, Wallis found an
increase in other granulomatous infections (histoplasma
and fungus) associated with infliximab compared with eta-
nercept (54 versus 32 cases per 100,000 patients treated;
p < 0.001) [4]. The risk for TB with etanercept use appears
to be less than for infliximab and adalimumab but is still
present.
Onset of TB in patients treated with anti-TNF-α
medications-immunologic mechanisms
As discussed previously, after TB enters the lungs of a
human host, most TB bacilli are ingested by alveolar
macrophages and DCs, and the tuberculosis bacilli are
isolated to the granuloma. Within the granuloma, accu-
mulated monocytes differentiate into epithelioid cells
and/or fuse to form giant cells. In the process, the pres-
ence of TNF-α is essential to a giant cell (Langhans-like
cell) formation and maintenance (Figure 4, [26]), as it
organizes granuloma in human body and functions in
surveillance [30,31]. The activation of focal adhesion
kinases are linked to cell assembling and the formation
of Langhans-like multinucleated giant cells [26].
In several clinical and experimental studies, when the
containment of the bacteria in granulomas is obstructed
by TNF-α neutralizing inhibitors (the biologics) previously
latent TB bacilli may cause a disseminated TB disease
[3,4,30,31]. TNF signaling via TNF receptor-1 (TNF-R1)
appears to be particularly required for host resistance to
mycobacterial infection [32-34]. In a comparison of recep-
tor knockout (KO) mice infected with Mycobacterium
bovis, it was found that, while the bacterial burden of
TNF-R1-deficient mice was significantly increased and the
mice succumbed to mycobacterial infection, TNF-R2 KOaracterization of peripheral blood monocytes that are cultured in
-α (20 ng/mL) are demonstrated. Representative images of cultured
Langhans-like cells are observed in the presence of TNF-α GM-CSF,
rleukin-4; TNF, tumor necrosis factor.
Figure 5 Key functions of the tumor necrosis factor (TNF)-α cytokine in tuberculosis. (A) TNF-α recruits neutrophils, macrophages and
T-lymphocytes to the infection site; (B) The cytokine maintains granuloma formation in tuberculosis; (C) The autocrinal TNF-α is also produced
and induces apoptosis of TB-infected cells.
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ciated with severe impairment in forming granulomas,
with reduced macrophage recruitment and activation
and diminished expression of adhesion molecules [36,37].
Thus, anti-mycobacterial immunity is largely dependent
on TNF signaling via the TNF-R1, while the activation of
TNF-R2 appears to play a minor role [4,35].
Etanercept is a diametric fusion protein consisting of two
extracellular domains of the p55 TNF receptor (TNF-R1)
and p75 TNF receptor (TNF-R2). The proinflammatory
reaction through TNF-R2 is completely inhibited with
etanercept, compared to that throughTNF-R1, which is less
inhibited. This may explain the relative decreased risk of
TB in patients treated with etanercept compared to patients
treated with infliximab or adalimumab.
In the human body, for the sterilization of TB bacillus
in macrophages, the superoxide radical (peroxynitrite)
production and the killing protein are also important;
the sterilization is activated by IFN-γ in monocytes and
macrophages [4,31]. IFN-γ is capable of inducing CTL
activity to mycobacterium-infected cells.
Experiments of nature have greatly elucidated the patho-
physiology of immune disorders and susceptibility to TB.
Chronic granulomatous disease, a congenital immuno-
deficiency, is associated with a lack of superoxide anionproduction in phagocytes and patients with this disorder
are highly susceptible to mycobacteria. Mendelian suscep-
tibility to mycobacterial infection disease (MSMD) is
caused by the inherited deficiency of IFN –γ and IL-12-
induced signal transduction [38,39]. In addition, as we
have discussed, anti-TNF-α therapy induces disseminated
tuberculosis, obstructing granuloma formation. We can
now conclude that the cytokines TNF-α and IFN-γ and
superoxide anion production are essential to immunity
against Mycobacterium tuberculosis.
Anti-TNF-α inhibitors in Kawasaki disease
Infliximab, which is a neutralizing TNF inhibitor, has re-
cently attracted attention as a therapy for Kawasaki disease
(KD). This disease is at times severe and intractable, even
with IVIG therapy. Infliximab significantly shortens fever
duration and may obstruct coronary lump formation in
KD [40,41]. In such cases, excessive screening for latent
tuberculosis infection and hesitation in the treatment may
be ill-advised. Because a granuloma lesion (latent infec-
tion) of tuberculosis is overall less common in early
childhood, the treatment with infliximab should be
quickly administered in children with Kawasaki disease,
when other treatments fail. From our literature review,
we believe that this short-term usage of TNF inhibitors
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mary tuberculosis.
Vaccines and anti-TNF-α medications
In 1998, the United States Centers for Disease Control
announced that novel vaccines should be used in place of
Bacille de Calmette et Guérin (BCG; M. bovis) for protec-
tion against tuberculosis worldwide. Yet BCG still remains
in use throughout the world. Although the protective effi-
cacy is well established against TB infection and its progres-
sion to clinical diseases during childhood [42], persistency
of protective efficacy (cytotoxic CD8+ Tcell activity) against
M. tuberculosis is not fully provided with BCG vaccine
outside the first decades of life. The development of a more
effective vaccine against M. tuberculosis in the near future
is highly desirable not only for the prevention of early
progression of primary tuberculosis but also for the decline
of patients infected with disseminated tuberculosis induced
by aging and/or TNF-α inhibitors.
Conclusions
The development of biologics is revolutionizing the treat-
ment of immune-mediated inflammatory diseases such as
RA, inflammatory bowel disease and juvenile idiopathic
arthritis. On the other hand, this interception of inflam-
matory cytokines such as TNF-α, which are direct factors
in the creation of inflammation, may restrain protective
physiological reactions and cause reactions that can revive
infectious diseases such as TB that are in dormancy. Rheu-
matologists, gastroenterologists, and other care providers
prescribing biologics should understand these compli-
cations well and be familiar with the current knowledge
of the roles of TNF- α in the human host as well as the
pathophysiologic mechanisms of the TNF-α blockers in
the development of secondary (disseminated) tuberculosis.
Clinicians should be vigilant for TB and granulomatous
infections when prescribing TNF inhibitors and other
biologics and manage these side effects as a crucial com-
ponent of the disease treatment.
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